Description

Glaukos Corporation: These Are The 4 Reasons Why We Are Relatively Less Optimistic! 

Glaukos Corporation’s second quarter earnings for 2024 revealed a 19% increase in consolidated net sales which amounted to $95.7 million, reflecting consistent growth across both U.S. and international markets, particularly in the glaucoma division. The company has upwardly revised its full-year net sales guidance for 2024 to $370 million – $376 million, indicating optimistic projections based on current performance.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!